First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in BRAF- and RAS-mutant cell lines. In this multicenter phase I trial (NCT01781429), 135 patients were enrolled to an accelerated 3 + 3 dose-escalation cohort and six distinct dose-expansion cohorts. Dose escalation...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer discovery Vol. 8; no. 2; p. 184
Main Authors:	Sullivan, Ryan J, Infante, Jeffrey R, Janku, Filip, Wong, Deborah Jean Lee, Sosman, Jeffrey A, Keedy, Vicki, Patel, Manish R, Shapiro, Geoffrey I, Mier, James W, Tolcher, Anthony W, Wang-Gillam, Andrea, Sznol, Mario, Flaherty, Keith, Buchbinder, Elizabeth, Carvajal, Richard D, Varghese, Anna M, Lacouture, Mario E, Ribas, Antoni, Patel, Sapna P, DeCrescenzo, Gary A, Emery, Caroline M, Groover, Anna L, Saha, Saurabh, Varterasian, Mary, Welsch, Dean J, Hyman, David M, Li, Bob T
Format:	Journal Article
Language:	English
Published:	United States 01.02.2018
Subjects:	Adult Aged Aged, 80 and over Aminopyridines - pharmacology Aminopyridines - therapeutic use Female Humans Magnetic Resonance Imaging Male Middle Aged Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors Mitogen-Activated Protein Kinases - genetics Mitogen-Activated Protein Kinases - metabolism Mutation Neoplasm Staging Neoplasms - diagnosis Neoplasms - drug therapy Neoplasms - genetics Neoplasms - metabolism Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Pyrroles - pharmacology Pyrroles - therapeutic use Tomography, X-Ray Computed Treatment Outcome Young Adult
ISSN:	2159-8290, 2159-8290
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!